Literature DB >> 29097422

Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.

Brendan L Horton1, Jason B Williams1, Alexandra Cabanov2, Stefani Spranger1, Thomas F Gajewski3,4.   

Abstract

Subsets of human tumors are infiltrated with tumor antigen-specific CD8+ T cells [tumor-infiltrating lymphocytes (TILs)] despite tumor progression. These TILs are thought to be inactivated by the immunosuppressive tumor microenvironment, through the engagement of inhibitory receptors such as CTLA-4 and PD-1. However, antigen-specific CD8+ TILs are not functionally inert but are undergoing activation in situ Here, we show that antigen-specific CD8+ TILs are actively proliferating, yet also undergo high rates of apoptosis, leading to a vicious cycle of activation and death that limits immune efficacy. Preventing CD8+ TIL apoptosis by Bcl-xL overexpression enabled accumulation and improved tumor control. Effective combination immunotherapy with an agonist 4-1BB mAb plus either CTLA-4 or PD-L1 neutralization led to a marked accumulation of specific CD8+ TILs through decreased apoptosis rather than increased T-cell entry or proliferation. Our data suggest that antigen-driven apoptosis of CD8+ TILs is a barrier to effective spontaneous antitumor immunity and should be considered as a critical factor in the development of cancer immunotherapies. Cancer Immunol Res; 6(1); 14-24. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29097422      PMCID: PMC5754226          DOI: 10.1158/2326-6066.CIR-17-0249

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  31 in total

1.  Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Authors:  Bettina Weigelin; Elixabet Bolaños; Alvaro Teijeira; Ivan Martinez-Forero; Sara Labiano; Arantza Azpilikueta; Aizea Morales-Kastresana; José I Quetglas; Esther Wagena; Alfonso Rodríguez Sánchez-Paulete; Lieping Chen; Peter Friedl; Ignacio Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-01       Impact factor: 11.205

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

4.  Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone.

Authors:  K Udaka; K H Wiesmüller; S Kienle; G Jung; P Walden
Journal:  J Immunol       Date:  1996-07-15       Impact factor: 5.422

5.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

Authors:  Adil I Daud; Kimberly Loo; Mariela L Pauli; Robert Sanchez-Rodriguez; Priscila Munoz Sandoval; Keyon Taravati; Katy Tsai; Adi Nosrati; Lorenzo Nardo; Michael D Alvarado; Alain P Algazi; Miguel H Pampaloni; Iryna V Lobach; Jimmy Hwang; Robert H Pierce; Iris K Gratz; Matthew F Krummel; Michael D Rosenblum
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

6.  Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Authors:  Anirban Banerjee; Krishnamurthy Thyagarajan; Shilpak Chatterjee; Paramita Chakraborty; Pravin Kesarwani; Myroslawa Soloshchenko; Mazen Al-Hommrani; Kristina Andrijauskaite; Kelly Moxley; Harinarayanan Janakiraman; Matthew J Scheffel; Kristi Helke; Kent Armenson; Viswanathan Palanisamy; Mark P Rubinstein; Elizabeth-Garrett Mayer; David J Cole; Chrystal M Paulos; Michael I Nishimura; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2016-07-27       Impact factor: 12.701

7.  T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.

Authors:  Ivan Martinez-Forero; Arantza Azpilikueta; Elixabet Bolaños-Mateo; Estanislao Nistal-Villan; Asis Palazon; Alvaro Teijeira; Gema Perez-Chacon; Aizea Morales-Kastresana; Oihana Murillo; Maria Jure-Kunkel; Juan M Zapata; Ignacio Melero
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

8.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Hypoxia-induced reactive oxygen species cause chromosomal abnormalities in endothelial cells in the tumor microenvironment.

Authors:  Miyako Kondoh; Noritaka Ohga; Kosuke Akiyama; Yasuhiro Hida; Nako Maishi; Alam Mohammad Towfik; Nobuo Inoue; Masanobu Shindoh; Kyoko Hida
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

View more
  61 in total

Review 1.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

2.  Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.

Authors:  Derek B Danahy; Isaac J Jensen; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2019-04-10       Impact factor: 5.422

Review 3.  T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.

Authors:  Jin Bian; Jianzhen Lin; Junyu Long; Xu Yang; Xiaobo Yang; Xin Lu; Xinting Sang; Haitao Zhao
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.

Authors:  Robert D Leone; Liang Zhao; Judson M Englert; Im-Meng Sun; Min-Hee Oh; Im-Hong Sun; Matthew L Arwood; Ian A Bettencourt; Chirag H Patel; Jiayu Wen; Ada Tam; Richard L Blosser; Eva Prchalova; Jesse Alt; Rana Rais; Barbara S Slusher; Jonathan D Powell
Journal:  Science       Date:  2019-11-07       Impact factor: 47.728

5.  Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.

Authors:  Derek B Danahy; Samarchith P Kurup; Christina S Winborn; Isaac J Jensen; John T Harty; Thomas S Griffith; Vladimir P Badovinac
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

6.  T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Authors:  Tori N Yamamoto; Ping-Hsien Lee; Suman K Vodnala; Devikala Gurusamy; Rigel J Kishton; Zhiya Yu; Arash Eidizadeh; Robert Eil; Jessica Fioravanti; Luca Gattinoni; James N Kochenderfer; Terry J Fry; Bulent Arman Aksoy; Jeffrey E Hammerbacher; Anthony C Cruz; Richard M Siegel; Nicholas P Restifo; Christopher A Klebanoff
Journal:  J Clin Invest       Date:  2019-02-25       Impact factor: 14.808

7.  Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Authors:  Ila Datar; Miguel F Sanmamed; Jun Wang; Brian S Henick; Jungmin Choi; Ti Badri; Weilai Dong; Nikita Mani; Maria Toki; Luis D Mejías; Maria D Lozano; Jose Luis Perez-Gracia; Vamsidhar Velcheti; Matthew D Hellmann; Justin F Gainor; Kristen McEachern; David Jenkins; Konstantinos Syrigos; Katerina Politi; Scott Gettinger; David L Rimm; Roy S Herbst; Ignacio Melero; Lieping Chen; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2019-05-03       Impact factor: 12.531

8.  Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.

Authors:  Priyamvada Jayaprakash; Midan Ai; Arthur Liu; Pratha Budhani; Todd Bartkowiak; Jie Sheng; Casey Ager; Courtney Nicholas; Ashvin R Jaiswal; Yanqiu Sun; Krishna Shah; Sadhana Balasubramanyam; Nan Li; Guocan Wang; Jing Ning; Anna Zal; Tomasz Zal; Michael A Curran
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

Review 9.  Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.

Authors:  Michael-Joseph Gorbet; Ashish Ranjan
Journal:  Pharmacol Ther       Date:  2019-12-19       Impact factor: 12.310

10.  Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection.

Authors:  Georgia M Beasley; Aaron D Therien; Eda K Holl; Rami Al-Rohil; Maria Angelica Selim; Nellie E Farrow; Liuliu Pan; Premi Haynes; Yan Liang; Douglas S Tyler; Brent A Hanks; Smita K Nair
Journal:  Cancer Immunol Immunother       Date:  2020-08-19       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.